New Therapeutic Strategies for Primary Sclerosing Cholangitis

Seminars in Liver Disease

Volumn 36, Issue 1, 2016, Pages 5-14

  Williamson, Kate D ^a   Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

cholangiocarcinoma; Crohn's disease; inflammatory bowel disease; primary sclerosing cholangitis; ulcerative colitis

Indexed keywords

AZATHIOPRINE; BEZAFIBRATE; COLCHICINE; CYCLOSPORIN; MARALIXIBAT CHLORIDE; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MITOMYCIN; OBETICHOLIC ACID; PENICILLAMINE; PLACEBO; PREDNISOLONE; RETINOIC ACID; SIMTUZUMAB; TACROLIMUS; URSODEOXYCHOLIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; BILE ACID; CHOLAGOGUE;

ARTICLE; BALLOON; BALLOON DILATATION; BILIARY STENT; CELL HOMING; DRUG EFFICACY; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; STUDY DESIGN; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; CHOLANGITIS, SCLEROSING; DRUG EFFECTS; GASTROINTESTINAL ENDOSCOPY; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; ENDOSCOPY, GASTROINTESTINAL; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MOLECULAR TARGETED THERAPY; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84958182341     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1571274     Document Type: Article

References (103)

1. Molodecky N. A., Kareemi H., Parab R., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology: 2011; 53 5 1590 1599
2. Boonstra K., Weersma R. K., van Erpecum K. J., et al. EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology: 2013; 58 6 2045 2055
3. Broomé U., Olsson R., Lööf L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut: 1996; 38 4 610 615
4. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol: 2009; 51 2 237 267
5. Chapman R., Fevery J., Kalloo A., et al. American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology: 2010; 51 2 660 678
6. National Health and Blood Service Annual Report on Liver Transplantation-Report for 2013/2014. Available at: http://www.odt.nhs.uk/pdf/organ-specific-report-liver-2014.pdf. Accessed March 8, 2015
7. Stanich P. P., Björnsson E., Gossard A. A., Enders F., Jorgensen R., Lindor K. D. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis: 2011; 43 4 309 313
8. Lindström L., Hultcrantz R., Boberg K. M., Friis-Liby I., Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol: 2013; 11 7 841 846
9. Al Mamari S., Djordjevic J., Halliday J. S., Chapman R. W. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol: 2013; 58 2 329 334
10. Rupp C., Rössler A., Halibasic E., et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther: 2014; 40 11-12 1292 1301
11. Poupon R. Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation. Hepatology: 2015; 61 6 2080 2090
12. Williamson K. D., Chapman R. W. Editorial: further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in PSC. Aliment Pharmacol Ther: 2015; 41 1 149 151
13. Tung B. Y., Emond M. J., Haggitt R. C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med: 2001; 134 2 89 95
14. Pardi D. S., Loftus E. V. Jr., Kremers W. K., Keach J., Lindor K. D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology: 2003; 124 4 889 893
15. Wolf J. M., Rybicki L. A., Lashner B. A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther: 2005; 22 9 783 788
16. Eaton J. E., Silveira M. G., Pardi D. S., et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol: 2011; 106 9 1638 1645
17. Lindström L., Boberg K. M., Wikman O., et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther: 2012; 35 4 451 457
18. Singh S., Khanna S., Pardi D. S., Loftus E. V. Jr., Talwalkar J. A. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis: 2013; 19 8 1631 1638
19. Karlsen T. H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology: 2010; 138 3 1102 1111
20. Ellinghaus D., Folseraas T., Holm K., et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology: 2013; 58 3 1074 1083
21. Liu J. Z., Hov J. R., Folseraas T., et al. UK-PSCSC Consortium; International IBD Genetics Consortium; International PSC Study Group. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet: 2013; 45 6 670 675
22. Hirschfield G. M., Karlsen T. H., Lindor K. D., Adams D. H. Primary sclerosing cholangitis. Lancet: 2013; 382 9904 1587 1599
23. Eksteen B., Grant A. J., Miles A., et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med: 2004; 200 11 1511 1517
24. Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Br Med Bull: 2014; 110 1 89 98
25. Lindkvist B., Benito de Valle M., Gullberg B., Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology: 2010; 52 2 571 577
26. Boonstra K., Beuers U., Ponsioen C. Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol: 2012; 56 5 1181 1188
27. Kim W. R., Poterucha J. J., Wiesner R. H., et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology: 1999; 29 6 1643 1648
28. Banerjee R., Pavlides M., Tunnicliffe E. M., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol: 2014; 60 1 69 77
29. de Vries E. MG, Beuers U., Ponsioen C. Y. Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol: 2015; 31 3 239 246
30. Vesterhus M., Hov J. R., Holm A., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology: 2015; 62 1 188 197
31. Okazaki K., Uchida K., Koyabu M., Miyoshi H., Ikeura T., Takaoka M. IgG4 cholangiopathy: current concept, diagnosis, and pathogenesis. J Hepatol: 2014; 61 3 690 695
32. Ngu J. H., Gearry R. B., Wright A. J., Stedman C. A. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol: 2011; 9 12 1092 1097, quiz e135
33. Björnsson E., Boberg K. M., Cullen S., et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut: 2002; 51 5 731 735
34. O'Brien C. B., Senior J. R., Arora-Mirchandani R., Batta A. K., Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology: 1991; 14 5 838 847
35. Beuers U., Spengler U., Kruis W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology: 1992; 16 3 707 714
36. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W. J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol: 1994; 20 1 57 64
37. De Maria N., Colantoni A., Rosenbloom E., Van Thiel D. H. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology: 1996; 43 12 1472 1479
38. Lindor K. D.; Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med: 1997; 336 10 691 695
39. van Hoogstraten H. JF, Wolfhagen F. HJ, van de Meeberg P. C., et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol: 1998; 29 3 417 423
40. Mitchell S. A., Bansi D. S., Hunt N., Von Bergmann K., Fleming K. A., Chapman R. W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology: 2001; 121 4 900 907
41. Harnois D. M., Angulo P., Jorgensen R. A., Larusso N. F., Lindor K. D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol: 2001; 96 5 1558 1562
42. Olsson R., Boberg K. M., de Muckadell O. S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology: 2005; 129 5 1464 1472
43. Lindor K. D., Kowdley K. V., Luketic V. A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology: 2009; 50 3 808 814
44. Lo S. K., Hermann R., Chapman R. WC., et al. Ursodeoxycholic acid in primary sclerosing cholangitis: a double-blind placebo controlled trial. Hepatology: 1992; 16 (S4): 92A
45. Wunsch E., Trottier J., Milkiewicz M., et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology: 2014; 60 3 931 940
46. Tabibian J. H., Lindor K. D. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology: 2014; 60 3 785 788
47. University of Tennessee Safety and efficacy study of ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01088607. Accessed July 30, 2015
48. Schramm C., Schirmacher P., Helmreich-Becker I., Gerken G., zum Büschenfelde K. H., Lohse A. W. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med: 1999; 131 12 943 946
49. Sandborn W. J., Wiesner R. H., Tremaine W. J., Larusso N. F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut: 1993; 34 2 242 246
50. Knox T. A., Kaplan M. M. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol: 1991; 86 5 546 552
51. Knox T. A., Kaplan M. M. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology: 1994; 106 2 494 499
52. Talwalkar J. A., Gossard A. A., Keach J. C., Jorgensen R. A., Petz J. L., Lindor R. N. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int: 2007; 27 4 451 453
53. LaRusso N. F., Wiesner R. H., Ludwig J., MacCarty R. L., Beaver S. J., Zinsmeister A. R. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology: 1988; 95 4 1036 1042
54. Olsson R., Broomé U., Danielsson A., et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology: 1995; 108 4 1199 1203
55. Hommes D. W., Erkelens W., Ponsioen C., et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol: 2008; 42 5 522 526
56. Fickert P., Pollheimer M. J., Beuers U., et al. International PSC Study Group (IPSCSG). Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol: 2014; 60 6 1290 1303
57. Nakken K. E., Nygård S., Haaland T., et al. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ -) mice harbouring chronic cholangitis. Scand J Gastroenterol: 2007; 42 10 1245 1255
58. Barry-Hamilton V., Spangler R., Marshall D., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med: 2010; 16 9 1009 1017
59. Gilead Sciences Simtuzumab (GS-6624) in the prevention of progression of liver fibrosis in subjects with primary sclerosing cholangitis (PSC). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01672853. Accessed July 27, 2015
60. Gilead Sciences Inc Gilead announces data from phase 2 study of simtuzumab for previously untreated pancreatic cancer, 2015. Available at: http://www.gilead.com/news/press-releases/2014/9/gilead-announces-data-from-phase-2-study-of-simtuzumab-for-previously-untreated-pancreatic-cancer. Accessed July 27, 2015
61. Pellicciari R., Fiorucci S., Camaioni E., et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem: 2002; 45 17 3569 3572
62. Fiorucci S., Rizzo G., Antonelli E., et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther: 2005; 314 2 584 595
63. Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet: 2015; 385 9972 956 965
64. Fickert P., Fuchsbichler A., Moustafa T., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol: 2009; 175 6 2392 2405
65. Hirschfield G. M., Mason A., Luketic V., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology: 2015; 148 4 751 61.e8
66. Pharmaceuticals I. Obeticholic acid (OCA) in primary sclerosing cholangitis (PSC) (AESOP). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT02177136. Accessed July 27, 2015
67. He H., Mennone A., Boyer J. L., Cai S. Y. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology: 2011; 53 2 548 557
68. Yale University combination therapy with ursodeoxycholic acid (UDCA) and all-trans retinoic acid (ATRA) for treatment of primary sclerosing cholangitis. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01456468. Accessed July 31, 2015
69. Fickert P., Wagner M., Marschall H. U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology: 2006; 130 2 465 481
70. Halilbasic E., Fiorotto R., Fickert P., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology: 2009; 49 6 1972 1981
71. Dr. Falk Pharma GmbH Norursodeoxycholic acid in the treatment of primary sclerosing cholangitis (NUC-3). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01755507. Accessed July 27, 2015
72. Miethke A. G., Zhang W., Simmons J., et al. Pharmacological inhibition of ASBT changes bile composition and blocks progression of sclerosing cholangitis in mdr2 knockout mice. Hepatology: 2015;; August 21, 2015. DOI:10.1002/hep.27973 [e-pub ahead of print]
73. Shire. Open label study to evaluate safety and efficacy of LUM001 in patients with primary sclerosing cholangitis (CAMEO). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT02061540. Accessed July 31, 2015
74. Konieczna A., Lichnovka R., Erdosova B., Ehrmann J. The role of PPARs in MDR - a lesson from embryonic development. Neoplasma: 2009; 56 4 279 283
75. Oude Elferink R. P., Ottenhoff R., van Wijland M., Smit J. J., Schinkel A. H., Groen A. K. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest: 1995; 95 1 31 38
76. Halliday J. S., Chapman R. W. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue! J Gastroenterol Hepatol: 2011; 26 9 1345 1346
77. Kita R., Kita-Sasai Y., Hanaoka I., et al. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol: 2002; 97 7 1849 1851
78. Kurihara T., Maeda A., Shigemoto M., Yamashita K., Kamatani N. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol: 2003; 38 3 300 301
79. Kita R., Takamatsu S., Kimura T., Kokuryu H., Osaki Y., Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol: 2006; 41 7 686 692
80. Mizuno S., Hirano K., Tada M., et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol: 2010; 45 7 758 762
81. Mizuno S., Hirano K., Isayama H., et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci: 2015; 22 10 766 770
82. Trivedi P. J., Adams D. H. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun: 2013; 46 97 111
83. Grant A. J., Lalor P. F., Hübscher S. G., Briskin M., Adams D. H. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology: 2001; 33 5 1065 1072
84. Liaskou E., Karikoski M., Reynolds G. M., et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology: 2011; 53 2 661 672
85. University of Birmingham A trial of BTT1023 in patients with primary sclerosing cholangitis (BUTEO). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT02239211. Accessed July 31, 2015
86. O'Hara S. P., Tabibian J. H., Splinter P. L., LaRusso N. F. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol: 2013; 58 3 575 582
87. Yokoyama T., Komori A., Nakamura M., et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int: 2006; 26 4 467 476
88. Lichtman S. N., Keku J., Clark R. L., Schwab J. H., Sartor R. B. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology: 1991; 13 4 766 772
89. Lichtman S. N., Okoruwa E. E., Keku J., Schwab J. H., Sartor R. B. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest: 1992; 90 4 1313 1322
90. Färkkilä M., Karvonen A. L., Nurmi H., et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology: 2004; 40 6 1379 1386
91. Tabibian J. H., Weeding E., Jorgensen R. A., et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther: 2013; 37 6 604 612
92. Tabibian J. H., Gossard A., El-Youssef M., et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther: 2014
93. Stanford University. Primary sclerosing cholangitis with oral vancomycin by the study of its antimicrobial and immunomodulating effects (PSC). ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01802073. Accessed July 30, 2015
94. Brigham and Women's Hospital Fecal microbiota transplantation for the treatment of primary sclerosing cholangitis. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT02424175. Accessed July 30, 2015
95. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med: 2013; 368 5 407 415
96. Chapman M. H., Webster G. JM, Bannoo S., Johnson G. J., Wittmann J., Pereira S. P. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol: 2012; 24 9 1051 1058
97. Baluyut A. R., Sherman S., Lehman G. A., Hoen H., Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc: 2001; 53 3 308 312
98. Stiehl A., Rudolph G., Klöters-Plachky P., Sauer P., Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol: 2002; 36 2 151 156
99. Academisch Medisch Centrum-Universiteit van Amsterdam (AMC-UvA). Short-term stenting versus balloon dilatation for dominant strictures in primary sclerosing cholangitis. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01398917. Accessed July 31, 2015
100. John Hopkins University. Mitomycin C therapy for patients with primary sclerosing cholangitis. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01688024. Accessed July 31, 2015
101. Rahbar R., Jones D. T., Nuss R. C., et al. The role of mitomycin in the prevention and treatment of scar formation in the pediatric aerodigestive tract: friend or foe? Arch Otolaryngol Head Neck Surg: 2002; 128 4 401 406
102. Chung J. H., Cosenza M. J., Rahbar R., Metson R. B. Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study. Otolaryngol Head Neck Surg: 2002; 126 5 468 474
103. Eksteen B. Targeting of gut specific leucocyte recruitment in IBD by vedolizumab. Gut: 2015; 64 1 8 10